UK Researchers Achieve Breakthrough in Slowing Huntington's Disease Progression with Gene Therapy
UK scientists have achieved a historic milestone by slowing Huntington's disease progression through an innovative gene therapy, offering hope for future treatments and patient stability.
In a significant advancement in neurodegenerative disease treatment, UK scientists have successfully slowed the progression of Huntington's disease for the first time using a pioneering gene therapy. The groundbreaking trial, conducted at University College London (UCL), involved a novel treatment called AMT-130, which is administered directly into the brain via injection. This therapy introduces functional DNA into patient cells permanently, aiming to modify the genetic factors of the disease.
Results from the early-stage clinical trial indicated that some participants experienced a substantial reduction—up to 75%—in the speed of disease progression over three years. Out of 29 patients, those receiving the highest doses of AMT-130 showed the most notable slowdown. Remarkably, some patients' conditions stabilized, and at least one participant was able to return to work, highlighting the potential impact of this therapy.
Huntington's disease is caused by a single genetic mutation and currently has no cure. It affects approximately 8,000 people in the UK, impairing movement, cognition, and mood. The study's lead researcher, Ed Wild of UCL's Huntington's Disease Center, stated, "This result changes everything. Based on these findings, AMT-130 is likely to become the first licensed treatment to slow Huntington's disease, which is truly transformative."
Professor Mike Hanna, director at UCL's Queen Square Institute of Neurology, described the findings as a new chapter in gene therapy development, with potential implications for other neurodegenerative disorders. The company uniQure plans to submit an application for accelerated approval to the US Food and Drug Administration early next year, with subsequent submissions in the UK and Europe.
This breakthrough offers new hope for Huntington's patients and could pave the way for more effective treatments in the future.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Female-Specific Pathway in Brown Fat Enhances Energy Burn in Women
A groundbreaking study reveals a female-specific mechanism in brown adipose tissue that enhances energy expenditure. Centered on PGC-1α and estrogen, this pathway offers promising avenues for obesity and diabetes therapies. Source: https://medicalx.press.com/news/2025-09-female-specific-mechanism-energy-expenditure.html
Funding Cuts Threaten Cholera Control Efforts Across Africa
Funding reductions are undermining efforts to combat cholera in Africa, risking increased cases and deaths amid declining international support and infrastructure challenges.
Revolutionary Insights into How the Brain Converts Intentions Into Speech
New research from UCSF uncovers the crucial role of the middle precentral gyrus in transforming speech intentions into coordinated vocal movements, revolutionizing our understanding of language production in the brain.
Mouse Study Shows Tirzepatide Slows Growth of Obesity-Related Breast Cancer
A groundbreaking mouse study presented at ENDO 2025 shows that tirzepatide, an anti-obesity medication, can slow the growth of breast cancer linked to obesity. These findings may pave the way for new cancer treatments targeting obesity-related pathways.